

Integrating Invasive Diagnostic Methods in Interventional Cardiology

Daniel Chamié, MD

Interventional Cardiologist, Instituto Dante Pazzanese de Cardiologia

Director, OCT Core Laboratory, Cardiovascular Research Center

Sao Paulo, Brazil



CARDIOVASCULAR
RESEARCH CENTER



Instituto DANTE PAZZANESE
de Cardiologia

When Do I Think of an Adjunctive Method?

1. To define which lesion to treat

- Physiology vs. Imaging
- Defining the culprit

2. To Guide/Optimize the PCI

- Pre-PCI
- Post-PCI

3. To understand the mechanisms of stent failure

When Do I Think of an Adjunctive Method?

1. To define which lesion to treat

- Physiology vs. Imaging
- Defining the culprit

2. To Guide/Optimize the PCI

- Pre-PCI
- Post-PCI

3. To understand the mechanisms of stent failure

How to Approach This Patient?

64-yo female, HTN, Hypercholesterolemia, type II Diabetes Mellitus, prior MI
NSTEMI in the past 30 days, evolving w/ Stable Angina CCS II
Referred for coronary angiography w/o any non-invasive functional test assessment



Syntax Score: 27

Two Goals of Tx in Pts with Stable CAD

1. Improve Symptoms and Quality of Life

- Measured by “soft endpoints” (i.e. angina/QOL scales)


2. Improve Prognosis

- Measured by “harder endpoints” (i.e. death, MI)

Multiple Studies have Shown a Powerful Relationship Between Ischemia and Survival


1,137 pts with chest pain or suspected CAD

10-yr survival in 307 pts according to CAD and Thallium-201



Patients at risk:

Normal SPECT:	388	385	369	369	353	342	208	95
1-2 abnl segments:	554	544	528	518	498	783	327	168
≥3 abnl segments:	195	489	183	173	170	159	106	53




69	67	66	66	63	56	50	40	36	28	27
136	126	124	120	119	117	111	86	62	40	23
102	95	95	95	95	94	93	90	68	47	28

Vanzetto G, et al. Circulation 1999;100:1521-1527

Pavin D, et al. Eur Heart J 1997;18:69-77

Appropriateness of Revascularization and Outcomes in the UK



Prospective study of consecutive pts undergoing CAG at 3 London hospitals
 Before pts were recruited, 9-member expert panel rated the appropriateness of revascularization according to the RAND method assigning pts a score [1: highly inappropriate; 9: highly appropriate]





In Order for Revascularization to Provide a Benefit Perceived by Patients...

- The revascularization must be able to be done safely and with high quality and/or durability.
- The revascularization has to be performed on lesions that are actually causing symptoms or a reduction in quality of life (also possible in “asymptomatic” patients).
 - Ischemia-based lesion assessment

Anatomy vs. Physiology





Vessel area: 9.1 mm²
Lumen area: 2.1 mm²
Plaque burden: 76.9%




Vessel area: 14.5 mm²
Lumen area: 2.4 mm²
Plaque burden: 83.2%



Anatomy vs. Physiology



Vessel area: 6.2 mm²
Lumen Area: 1.7 mm²
Plaque Burden: 72.5%



Reclassification of the Patient's Risk

After FFR, Syntax Score = 5.0


PCI of the LCx

Pre-Dil
Apex 2.0 x 15 mm

After Pre-Dil

Biomatrix Flex
2.5 x 36 mm


Post-Dil
Quantum 2.5 x 20 mm



Final Angiographic Result



Relation Between Angio %DS and FFR (n=1,329)




IVUS MLA Cutoffs for Non-LM Stenosis

	N	FFR	MLA	AUC	Sens	Spec	PPV	NPV	Accuracy
Takagi [1999 Circ]	51	0.75	3.0	-	83%	92%	-	-	-
Briguori [2001 AJC]	53	0.75	4.0	-	92%	56%	38%	96%	64%
Ben-Dor [2012 Cardiovasc Revasc Med]	205	0.80	3.09	0.73	69%	72%	-	-	70%
Kang [2011 Circ Int]	236	0.80	2.4	0.80	90%	60%	37%	96%	68%
Kang [2012 AJC]	784	0.80	2.4	0.77	84%	63%	48%	90%	69%
Koo [2011 JACC Int]	267	0.80	2.75	0.81	69%	65%	27%	81%	67%
Gonzalo [2012 JACC]	47	0.80	2.36 IVUS	0.63	67%	65%	67%	65%	66%
Gonzalo [2012 JACC]	61	0.80	1.95 OCT	0.70	82%	63%	66%	80%	72%
Stone [TCT 2013]	544	0.80	2.9	-	66.3 %	65.9 %	46.7 %	81.3 %	66%

Influence of an Epicardial Stenosis in the Coronary Blood Flow Dynamics



Daniel Bernoulli
1700-1782




Pression drops across the lesions:

1. Increases with Longitudinal increase of the lesion (lesion length)
2. Increases with smaller lumen Area
3. Increases with Flow (which is not linear!)

FFR Guides You Where to Treat


- 61-yo male
- HTN, dyslipidemia, prior MI
- Stable Angina (CCS III)
- SPECT w/ anterior wall ischemia
- Diffuse disease in the LAD




FFR Also Tells You Where to Treat

Original Strategy: stent the subocclusive distal LAD only


LAD Pre



2.25/30 ZES Resolute




LAD After Stent




**I was quite happy with the angiographic result,
but...**

FFR for Diffuse Disease Assessment





FFR After Distal LAD Stent Implantation



FFR for Diffuse Disease Assessment

ZES Resolute 2.75/24 mm


Angio Control



FFR for Diffuse Disease Assessment



FFR After Mid LAD Stent Implantation



FFR for Diffuse Disease Assessment


ZES Resolute 3.0/24 mm




Angio Control



FFR for Diffuse Disease Assessment



FFR After Prox LAD Stent Implantation



2011 ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention

5.4. Adjunctive Diagnostic Devices

5.4.1. FFR: Recommendation

Class IIa

1. FFR is reasonable to assess angiographic intermediate coronary lesions (50% to 70% diameter stenosis) and can be useful for guiding revascularization decisions in patients with SIHD.^{12,97,484–486} (Level of Evidence: A)

See Online Data Supplement 23 for additional data regarding FFR.

The limitations of coronary angiography for determination of lesion severity have been well described. Angiography

nism of stent thrombosis.⁴⁹⁵ (Level of Evidence: C)

Class III: NO BENEFIT

1. IVUS for routine lesion assessment is not recommended when revascularization with PCI or CABG is not being contemplated. (Level of Evidence: C)

IVUS provides a unique coronary artery assessment of lesion characteristics, minimal and maximal lumen diameters, cross-sectional area, and plaque area. Diagnostic uses for IVUS include the assessment of angiographic indeterminate coronary artery stenoses, determination of the mechanism of stent restenosis or thrombosis, and postcardiac transplantation surveillance of CAD.^{488,490–492,499} For left main coronary artery stenoses, a minimal lumen diameter of <2.8 mm or a

Guidelines on myocardial revascularization

The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI)[†]

Table 33 Recommendations for specific percutaneous coronary intervention devices and pharmacotherapy




	Class ^a	Level ^b	Ref. ^c
FFR-guided PCI is recommended for detection of ischaemia-related lesion(s) when objective evidence of vessel-related ischaemia is not available.	I	A	15, 28

However, there Are Situations When Intravascular Imaging Is Preferred

58-yo male, HTN, type II diabetic, active smoker


Inferior wall STEMI in the previous 4 days → tenecteplase w/ reperfusion criteria

Referred for coronary angiography





FFR has Limited Role in the Acute Phase of a Myocardial Infarction

Transient edema and microvascular dysfunction in the acute phase of an MI (≤ 5 days) precludes maximal vasodilation of the infarcted territory, restricting coronary flow, and making the pressure drop across the stenosis during maximal hyperemia to be smaller than expected \rightarrow **underestimation of the FFR values**




Defining the Culprit




OCT has the Highest Sensitivity for Detection of Culprit Lesions

30 pts with AMI were assessed with OCT, angiography, and IVUS




Intermediate LM Stenosis: FFR




Intermediate LM Stenosis: FFR

Survival



No at risk	Months					
	0	12	24	36	48	60
FFR ≥ 0.80	136	103	72	52	38	26
FFR < 0.80	73	56	41	30	14	10

MACE




No at risk	Months					
	0	12	24	36	48	60
FFR ≥ 0.80	136	106	77	57	42	30
FFR < 0.80	73	56	40	29	15	10

Intermediate LM Stenosis: FFR


LM lesion rarely appear isolated (6-9%)

In the presence of a downstream stenosis, the FFR value across a LM lesion can be underestimated, depending on:


- *The severity of the distal stenosis*
- *Mass of myocardium at risk*



IVUS Determinants of LM FFR < 0.75




IVUS Criteria for Revascularization of Intermediate LM Stenosis – LITRO Study




IVUS Criteria for Revascularization of Intermediate LM Stenosis – LITRO Study

Survival-Free of Death, MI, and Any Revascularization



Survival-Free of Cardiac Death



When Do I Think of an Adjunctive Method?

1. To define which lesion to treat

- Physiology vs. Imaging
- Defining the culprit

2. To Guide/Optimize the PCI

- Pre-PCI
- Post-PCI


3. To understand the mechanisms of stent failure

Predictors and Outcomes of ST

– An IVUS Registry –

53 Pts with Stent Thrombosis 132 ± 125 h following stent deployment under IVUS guidance


IVUS Findings



94% of the pts had at least 1 of these findings

Use of Intravascular Imaging Pre-PCI


- Accurately measure vessel and lumen size to maximize stent dimensions.
- Identify proximal and distal reference segment landing zones and accurately select stent length.



Dx Reference

MLA

Prox Reference



LA: 3.96 mm²
Max. Diam: 2.68 mm

LA: 1.04 mm²
Max. Diam: 1.26 mm

LA: 2.52 mm²
Max. Diam: 2.12 mm



LA: 2.73 mm²
Max. Diam: 2.07 mm

LA: 6.06 mm²
Max. Diam: 2.96 mm

Lesion Length: 22.5 mm

Use of Intravascular Imaging Post-PCI

- Maximize stent CSA relative to the vessel references.
- Full lesion coverage.
- Recognize/diagnose/treat complications



LA: 4.93 mm²
Max. Diam: 2.57 mm

LA: 5.38 mm²
Max. Diam: 2.64 mm


LA: 5.78 mm²
Max. Diam: 2.83 mm

LA: 6.06 mm²
Max. Diam: 2.98 mm




LA: 6.42 mm²
Max. Diam: 2.91 mm

Use of Intravascular Imaging Post-PCI




61 Year-old male, HTN, smoker, previous PCI. Presenting with stable angina (CCS II)






Acceptable Angiographic Result, Non-Ischemic FFR, but ...






Acceptable Angiographic Result, Non-Ischemic FFR, but ...






Acceptable Angiographic Result, Non-Ischemic FFR, but ...



Acceptable Angiographic Result, Non-Ischemic FFR, but ...



Acceptable Angiographic Result, Non-Ischemic FFR, but ...



Meta-Analysis of DES Studies (n=17,570)

Compared with angiographic guidance, IVUS-guided DES implantation was associated with reduced rates of:

- Death**

HR 0.58 (0.47-0.71), $p < 0.001$


- MACE**

HR 0.85 (0.76-0.95), $p = 0.005$

- Stent Thrombosis**

HR 0.62 (0.46-0.83), $p = 0.002$

Note: TLR HR 0.90 (0.73-1.11) all studies;
0.63 (0.46-1.14) propensity-adjusted studies



ADAPT-DES

Prospective, multicenter, real-world registry of 8,583 consecutive pts undergoing DES implantation to determine the frequency, timing, and correlates of early and late ST.

During the index procedure, IVUS was used in 3,349 pts

	IVUS (n=3,349)	No IVUS (n=5,234)	P
Any ST within 1 year	0.52%	1.04%	0.011
<i>Acute</i>	0.06%	0.04%	0.66
<i>Subacute</i>	0.27%	0.56%	0.05
<i>Late</i>	0.25%	0.48%	0.10
All-cause death/MI within 1 year	3.96%	5.35%	0.004
Cardiac death within 1 year	0.84%	1.19%	0.12
Peri-procedural MI	1.26%	1.53%	0.29
ST-related MI	0.37%	0.59%	0.16%
Non-ST-related MI	0.87%	1.58%	0.0054
Ischemia-driven TVR	2.42%	3.95%	0.0001


Impact of OCT on PCI Management

Pre-Intervention

Any Change Based on OCT: **81.8%**

Post-Intervention

Any Change Based on OCT: **54.8%**



OCT-Guided PCI


335 pts who underwent PCI guided by angiography + OCT were compared with a paired group of another 335 pts who underwent PCI under angiography guidance only during the same period (within 30 days)

	Angiographic guidance group (n=335)	Angiographic plus OCT guidance group (n=335)	p-value
In-hospital events			
Cardiac death	3 (0.9%)	2 (0.6%)	1.0
Non-fatal myocardial infarction	22 (6.5%)	13 (3.9%)	0.118
Events at 1-year follow-up			
Death	23 (6.9%)	11 (3.3%)	0.035
Cardiac death	15 (4.5%)	4 (1.2%)	0.010
Myocardial infarction	29 (8.7%)	18 (5.4%)	0.096
Target lesion repeat revascularisation	11 (3.3%)	11 (3.3%)	1.0
Definite stent thrombosis	2 (0.6%)	1 (0.3%)	1.0
Cardiac death or myocardial infarction	43 (13.0%)	22 (6.6%)	0.006
Cardiac death, myocardial infarction, or repeat revascularisation	50 (15.1%)	32 (9.6%)	0.034

OCT-guided PCI independently associated with reduced risk of death and MI

- Multivariable logistic regression analysis: **OR: 0.49** [0.25-0.960, p=0.037]
- Propensity score adjustment: **OR: 0.37** [0.10-0.90], p=0.050
- Cox proportional hazard analysis: **HR: 0.51** [0.28-0.93], p=0.028

3D-OCT: Global Stent Geometry Assessment



When Do I Think of an Adjunctive Method?

1. To define which lesion to treat

- Physiology vs. Imaging
- Defining the culprit

2. To Guide/Optimize my PCI


- Pre-PCI
- Post-PCI

3. To understand the mechanisms of stent failure









Understanding the Mechanisms of Stent Failure

62-yo male, HTN, dyslipidemia
PCI to LAD w/ SES in Aug/2003
DAPT for 3 mos
Asymptomatic for 5 years
Jun/2008 → NSTEMI

54-yo male, HTN, type II DM
Prior MI (May/2007); PCI to LAD w/ PES
DAPT for 12 mos
Asymptomatic for 3.9 years
Feb/2011 → Anterior wall STEMI



Understanding the Mechanisms of Stent Failure – Case 1: Incomplete Healing




Two Late DES Failures with the Same Clinical Impact; Two Different Mechanisms; Two Different Solutions

PCI with a 3.0x24 mm BMS Implantation



PCI with a 3.5x23 mm EES Implantation



Summary

1. Physiology should be the first choice for determining which lesion to treat.
 - Intravascular imaging (particularly OCT) may have a role in the ACS setting in identifying the culprit lesion.
 - For assessment of intermediate LM lesions, FFR and IVUS have demonstrated good prognostic applicability.
 - Due to the inherent limitations of FFR for assessment of LM lesions, IVUS-derived MLA cut-offs can be a more practical approach.
2. For Guidance/Optimization of PCI Results:
 - FFR has limited role.
 - IVUS and OCT can be used.
 - Large body of evidence with IVUS / Studies are ongoing with OCT.
 - OCT is more sensitive than IVUS for detection malapposition, dissections, plaque prolapse, and thrombus – clinical impact needs further studies.
3. For Identification of the Mechanisms of Stent Failure:
 - IVUS and OCT are useful in identifying regions of underexpansion and ISA.
 - OCT is more sensitive for ISA detection, and allows for:
 - strut level assessment – strut coverage and apposition
 - qualitative assessment of NIH – neoatherosclerosis, peri-strut infiltrates, etc

Conclusions

1. One of the legacies of coronary angiography is to assume that one technique will always answer all questions, but that is not the current state-of-the-art.
2. Barriers to implementing an intravascular imaging and physiology program:
 - **Cost** – unfortunately, the cost of these techniques can dwarf that of other materials used in PCI
 - **Expertise**
 - Interpretation is not intuitive, and requires training.
 - Understanding the artifacts, limitations, and confounders of the adjunct methods is critical for its proper use.
 - **Being aware** of the **limitations** of relying on **coronary angiography** alone for specific situations





**Istituto DANTE PAZZANESE
de Cardiologia**







Do I Need to Treat These Lesions?

62-yo male, HTN, type II DM, Dyslipidemia, Former smoker
Stable Angina (CCS II) for 2 months

Referred to coronary angiography w/o any non-invasive functional test




Two Lesions with the Same Anatomic Stenosis Severity, but Different Physiological Responses




IVUS Criteria of “Optimal Stent Implantation”

– Drug-Eluting Stent Era –


Cypher¹




Taxus²



Endeavor³



Xience V³



¹Sonoda S et al. JACC 2004;43:1959-1963 / ²Doi H, et al. JACC Cardiovasc Interv 2009;2:1269-1275 / ³Song HG, et al. Catheter Cardiovasc Interv 2012; pubmed ahead of print